Production (Stage)
Maze Therapeutics, Inc.
MAZE
$12.93
-$0.41-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -- | -- | -- | 24.83M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | -- | 101.43M | |
| Operating Income | -- | -- | -- | -101.43M | |
| Income Before Tax | -- | -- | -- | -108.36M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | -- | -108.36 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | -- | -108.36M | |
| EBIT | -- | -- | -- | -101.43M | |
| EBITDA | -- | -- | -- | -97.44M | |
| EPS Basic | -- | -- | -- | -46.94 | |
| Normalized Basic EPS | -- | -- | -- | -27.03 | |
| EPS Diluted | -- | -- | -- | -46.95 | |
| Normalized Diluted EPS | -- | -- | -- | -27.03 | |
| Average Basic Shares Outstanding | -- | -- | -- | 9.23M | |
| Average Diluted Shares Outstanding | -- | -- | -- | 9.23M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |